Early glycoprotein IIb–IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis

Background: Even though time-to-treatment has been shown to be a determinant of mortality in primary angioplasty, the potential benefits from early pharmacological reperfusion by glycoprotein (Gp) IIb–IIIa inhibitors are still unclear. The aim of this meta-analysis was to combine individual data from all randomised trials conducted on facilitated primary angioplasty by the use of early Gp IIb–IIIa inhibitors. Methods and results: The literature was scanned by formal searches of electronic databases (MEDLINE, EMBASE) from January 1990 to October 2007. All randomised trials on facilitation by the early administration of Gp IIb–IIIa inhibitors in ST-segment elevation myocardial infarction (STEMI) were examined. No language restrictions were enforced. Individual patient data were obtained from 11 out of 13 trials, including 1662 patients (840 patients (50.5%) randomly assigned to early and 822 patients (49.5%) to late Gp IIb–IIIa inhibitor administration). Preprocedural Thrombolysis in Myocardial Infarction Study (TIMI) grade 3 flow was more frequent with early Gp IIb–IIIa inhibitors. Postprocedural TIMI 3 flow and myocardial blush grade 3 were higher with early Gp IIb–IIIa inhibitors but did not reach statistical significance except for abciximab, whereas the rate of complete ST-segment resolution was significantly higher with early Gp IIb–IIIa inhibitors. Mortality was not significantly different between groups, although early abciximab demonstrated improved survival compared with late administration, even after adjustment for clinical and angiographic confounding factors. Conclusions: This meta-analysis shows that pharmacological facilitation with the early administration of Gp IIb–IIIa inhibitors in patients undergoing primary angioplasty for STEMI is associated with significant benefits in terms of preprocedural epicardial recanalisation and ST-segment resolution, which translated into non-significant mortality benefits except for abciximab.

[1]  E. Topol,et al.  Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events). , 2010, JACC. Cardiovascular interventions.

[2]  E. Topol,et al.  1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial. , 2009, JACC. Cardiovascular interventions.

[3]  K. Eagle,et al.  Outcomes with the use of glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromes , 2007, Heart.

[4]  M. Leoncini,et al.  Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI Trial). , 2007, Journal of the American College of Cardiology.

[5]  D. Sorysz,et al.  Early abciximab administration before primary percutaneous coronary intervention improves infarct-related artery patency and left ventricular function in high-risk patients with anterior wall myocardial infarction: a randomized study. , 2007, American heart journal.

[6]  E. Vicaut,et al.  Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. , 2007, European heart journal.

[7]  K. Yeşilçimen,et al.  Impact of Early Tirofiban Administration on Myocardial Salvage in Patients with Acute Myocardial Infarction Undergoing Infarct-Related Artery Stenting , 2006, Cardiology.

[8]  E. Braunwald,et al.  Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial. , 2006, American heart journal.

[9]  H. Gabriel,et al.  Early administration of abciximab bolus in the emergency department improves angiographic outcome after primary PCI as assessed by TIMI frame count: Results of the early ReoPro administration in myocardial infarction (ERAMI) trial , 2006, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[10]  J. Boura,et al.  Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials , 2006, The Lancet.

[11]  P. Armstrong,et al.  Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial , 2006, The Lancet.

[12]  Duolao Wang,et al.  Early versus periprocedural administration of abciximab for primary angioplasty: a pooled analysis of 6 studies. , 2005, American heart journal.

[13]  S. Iliceto,et al.  Duration of ischemia is a major determinant of transmurality and severe microvascular obstruction after primary angioplasty: a study performed with contrast-enhanced magnetic resonance. , 2005, Journal of the American College of Cardiology.

[14]  R. Schiele,et al.  Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial. , 2005, European heart journal.

[15]  E. Antman,et al.  Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. , 2005, JAMA.

[16]  Harlan M Krumholz,et al.  Times to Treatment in Transfer Patients Undergoing Primary Percutaneous Coronary Intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 Analysis , 2005, Circulation.

[17]  E. Antman,et al.  Adjunctive abciximab to reperfusion therapy in patients with acute st-segment elevation myocardial infarction: A meta-analysis of randomized trials , 2005 .

[18]  K. Huber,et al.  Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion - results of the Austrian multi-centre randomized ReoPro-BRIDGING Study. , 2004, European heart journal.

[19]  J. Ottervanger,et al.  Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction. , 2004, Journal of the American College of Cardiology.

[20]  J. Ottervanger,et al.  Time-to-treatment significantly affects the extent of ST-segment resolution and myocardial blush in patients with acute myocardial infarction treated by primary angioplasty. , 2004, European heart journal.

[21]  H. Suryapranata,et al.  Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial. , 2004, European heart journal.

[22]  H. Suryapranata,et al.  Preprocedural TIMI flow and mortality in patients with acute myocardial infarction treated by primary angioplasty. , 2004, Journal of the American College of Cardiology.

[23]  Elliott M. Antman,et al.  Time Delay to Treatment and Mortality in Primary Angioplasty for Acute Myocardial Infarction: Every Minute of Delay Counts , 2004, Circulation.

[24]  B. Witzenbichler,et al.  1022-79 Is early prehospital administration of abciximab superior to periprocedural therapy in patients with ST-segment elevation myocardial infarction and planned percutaneous coronary intervention? Early and late results from the randomized REOMOBILE pilot study , 2004 .

[25]  D. Cutlip,et al.  Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction. , 2003, The American journal of cardiology.

[26]  R. Califf,et al.  Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Dichotomous response as a function of age in the GUSTO V trial. , 2003, European heart journal.

[27]  A. Yeung,et al.  Adjunctive Platelet Glycoprotein IIb/IIIa Receptor Inhibition With Tirofiban Before Primary Angioplasty Improves Angiographic Outcomes: Results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) Pilot Trial , 2003, Circulation.

[28]  J. Boura,et al.  Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction : a quantitative review of 23 randomised trials , 2022 .

[29]  N. Lakkis,et al.  Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban. , 2002, The American journal of cardiology.

[30]  M. Noc,et al.  Effects of abciximab pretreatment in patients with acute myocardial infarction undergoing primary angioplasty. , 2002, The American journal of cardiology.

[31]  C. Bode,et al.  The GP IIb/IIIa inhibitor abciximab (c7E3) inhibits the binding of various ligands to the leukocyte integrin Mac-1 (CD11b/CD18, αMβ2) , 2002 .

[32]  J. Ottervanger,et al.  Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction. , 2002, European heart journal.

[33]  R. Califf,et al.  Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials , 2002, The Lancet.

[34]  G. Stone,et al.  Normal Flow (TIMI-3) Before Mechanical Reperfusion Therapy Is an Independent Determinant of Survival in Acute Myocardial Infarction: Analysis From the Primary Angioplasty in Myocardial Infarction Trials , 2001, Circulation.

[35]  M. Morice,et al.  Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. , 2001, The New England journal of medicine.

[36]  R. Trawöger,et al.  [Thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) in 13 children: a case series]. , 2000, Wiener Klinische Wochenschrift.

[37]  K. Lee,et al.  Clinical trials in acute myocardial infarction: should we adjust for baseline characteristics? , 2000, American heart journal.

[38]  B. Coller Potential non-glycoprotein IIb/IIIa effects of abciximab. , 1999, American heart journal.

[39]  H. Suryapranata,et al.  Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group. , 1998, Circulation.

[40]  A. Jaffe,et al.  Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator. , 1992, Journal of the American College of Cardiology.

[41]  D L Demets,et al.  Methods for combining randomized clinical trials: strengths and limitations. , 1987, Statistics in medicine.

[42]  W. Ganz,et al.  The thrombolysis in myocardial infarction (TIMI) trial. , 1985, The New England journal of medicine.

[43]  C. Bode,et al.  The GP IIb/IIIa inhibitor abciximab (c7E3) inhibits the binding of various ligands to the leukocyte integrin Mac-1 (CD11b/CD18, alphaMbeta2). , 2002, Thrombosis research.

[44]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.